For research use only. Not for therapeutic Use.
PXL770 is a direct AMP kinase activator. PXL770 can be used in the research of non-alcoholic fatty liver disease (NAFLD)[1].
| Catalog Number | I040160 |
| CAS Number | 1523493-53-9 |
| Synonyms | 2-chloro-4-hydroxy-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one |
| Molecular Formula | C23H18ClNO3S |
| Purity | ≥95% |
| InChI | InChI=1S/C23H18ClNO3S/c24-21-17(15-11-10-12-6-4-5-9-14(12)19(15)26)18-20(27)16(13-7-2-1-3-8-13)22(28)25-23(18)29-21/h1-3,7-8,10-11,26H,4-6,9H2,(H2,25,27,28) |
| InChIKey | KPNBBJGVCJQHBR-UHFFFAOYSA-N |
| SMILES | C1CCC2=C(C1)C=CC(=C2O)C3=C(SC4=C3C(=C(C(=O)N4)C5=CC=CC=C5)O)Cl |
| Reference | [1]. Kenneth Cusi, et al. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Gastroenterol Hepatol. 2021, 6, 11. |
